Michael Bailey - AVEO Pharmaceuticals CEO and President Secretary and Director
CEO
Mr. Michael P. Bailey is President, Chief Executive Officer and Director of the Company effective January 6, 2015. Mr. Bailey joined company in September 2010 as Chief Commercial Officer and was named Chief Business Officer in June 2013. Prior to joining this company, Mr. Bailey served as senior vice president, business development and chief commercial officer at Synta Pharmaceuticals, a biopharmaceutical company, from August 2008 to September 2010. From 1999 to 2008, Mr. Bailey worked at ImClone, a biopharmaceutical company. During his nineyear tenure at ImClone, he was responsible for commercial aspects of the planning and launch of ERBITUX across multiple oncology indications, as well as new product planning for the ImClone development portfolio, which included CYRAMZA and necitumumab. In addition, Mr. Bailey was a key member of the strategic leadership committees for ImClone and its North American and worldwide partnerships and led their commercial organization, most recently as Senior Vice President of Commercial Operations. Prior to his role at ImClone. Mr. Bailey managed the cardiovascular development portfolio at Genentech, Inc., a biopharmaceutical company, from 1997 to 1999. Mr. Bailey started his career in the pharmaceutical industry as part of SmithKline Beechams Executive Marketing Development Program, where he held a variety of commercial roles from 1992 to 1997, including sales, strategic planning, and product management since 2015.
| Age | 58 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Phone | 857 400 0101 |
| Web | https://www.aveooncology.com |
AVEO Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1456) % which means that it has lost $0.1456 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7253) %, meaning that it created substantial loss on money invested by shareholders. AVEO Pharmaceuticals' management efficiency ratios could be used to measure how well AVEO Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.AVEO Pharmaceuticals currently holds 37.96 M in liabilities with Debt to Equity (D/E) ratio of 1.26, which is about average as compared to similar companies. AVEO Pharmaceuticals has a current ratio of 3.04, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about AVEO Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 8 records | CEO Age | ||
| John Donahoe | Nike Inc | 60 | |
| Elliott Hill | Nike Inc | 61 | |
| Kevin Clark | Aptiv PLC | 63 | |
| Nicole Sparshott | Unilever PLC ADR | N/A | |
| John II | Nike Inc | 63 | |
| Alan Jope | Unilever PLC ADR | 60 | |
| Benedetto Vigna | Ferrari NV | 56 | |
| Mark Parker | Nike Inc | 69 | |
Management Performance
| Return On Equity | -0.73 | |||
| Return On Asset | -0.15 |
AVEO Pharmaceuticals Leadership Team
Elected by the shareholders, the AVEO Pharmaceuticals' board of directors comprises two types of representatives: AVEO Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AVEO. The board's role is to monitor AVEO Pharmaceuticals' management team and ensure that shareholders' interests are well served. AVEO Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AVEO Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kevin Peacock, VP Marketing | ||
| Jeb Ledell, Chief Officer | ||
| Catherine DeRose, VP HR | ||
| Danielle Holland, VP Sec | ||
| David Crist, VP Sales | ||
| Lisa Bruneau, VP Treasurer | ||
| Emile Farhan, VP Operations | ||
| Michael Ferraresso, Chief Officer | ||
| CPA CFA, Chief Officer | ||
| Michael Bailey, CEO and President Secretary and Director |
AVEO Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AVEO Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.73 | |||
| Return On Asset | -0.15 | |||
| Profit Margin | (0.31) % | |||
| Operating Margin | (0.26) % | |||
| Current Valuation | 479.25 M | |||
| Shares Outstanding | 34.76 M | |||
| Shares Owned By Insiders | 0.19 % | |||
| Shares Owned By Institutions | 34.46 % | |||
| Number Of Shares Shorted | 816.84 K | |||
| Price To Earning | 158.21 X |
Pair Trading with AVEO Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AVEO Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AVEO Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Nike could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nike when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nike - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nike Inc to buy it.
The correlation of Nike is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nike moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nike Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nike can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in AVEO Stock
If you are still planning to invest in AVEO Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AVEO Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |